Breast Cancer Research and Treatment

, Volume 26, Issue 2, pp 139–147 | Cite as

A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens

  • Shun-Yuan Jiang
  • Christopher J. Parker
  • V. Craig Jordan
Article

Summary

The antiestrogen tamoxifen [(Z)-1(p-β-dimethylamino-ethoxyphenyl)-1,2-diphenylbut-1-ene] is an effective anticancer agent for the treatment of hormone responsive breast cancer. Previous studies have demonstrated that a point mutation in the estrogen receptor (ER) resulted in an alteration of the pharmacology of 4-hydroxytamoxifen, the active metabolite of tamoxifen (Jianget al, Mol Endocrinol 6:2167-2174, 1992). We have extended our studies to evaluate the effect of a point mutation, a Val substitution for Gly at amino acid 400 in the ligand binding domain of ER, on the pharmacology of other antiestrogens in ER stable transfectants derived from the ER-negative breast cancer cell line MDA-MB-231 CL10A. The compounds were tested with or without estradiol-17β (E2) for their effects on cell growth in cells expressing the wild type ER (S30) or the mutant ER (MLα2H) or in control antisense ER transfectant AS23 which does not express ER protein. MCF-7 cells, which express the wild type ER, were also used as a control. The growth of AS23 cells was not affected by any of the compounds at a concentration of 1 µM. E2 stimulated the growth of MCF-7 cells but inhibited the growth of ER transfectants S30 and MLα2H. The MLα2H cells were about 10 to 100-fold less sensitive to E2 and antiestrogens than S30 and MCF-7 cells. Keoxifene, an antiestrogen with a high affinity for the ER, maintained antiestrogenic activities in both ER transfectants and MCF-7 cells. However, the pharmacology of the steroidal antiestrogen RU 39411 was altered in the MLα2H cells. The compound did not block the effects of E2 but acted as an estrogen. Overall, this and previous studies from this laboratory demonstrate that it is possible to predict that the mutation will enhance the estrogenic activity of antiestrogens which have a side chain projecting in a position analogous to that of 4-hydroxytamoxifen. In contrast, compounds that do not have a side chain that occupies the same area, e.g. keoxifene and ICI 164,384, are unaffected by the mutation.

We have extended our previous model (Liebermanet al, J Biol Chem 258:4741-4745, 1983) to incorporate our new observations.

Key words

antiestrogens estrogen receptor tamoxifen keoxifene RU 39,411 drug resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harper MJK, Walpole AL: A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fert 13:101–119, 1967.Google Scholar
  2. 2.
    Early Breast Cancer Trialists' Collaborative Group: Effects of an adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl J Med 319:1681–1692, 1988.Google Scholar
  3. 3.
    Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183–5187, 1988.Google Scholar
  4. 4.
    Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for further clinical applications. Breast Cancer Res Treat 3 (Suppl 1): 73–86, 1983.Google Scholar
  5. 5.
    Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189–1195, 1987.Google Scholar
  6. 6.
    Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812–815, 1988.Google Scholar
  7. 7.
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C,et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i:117–120, 1989.Google Scholar
  8. 8.
    Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:306–316, 1977.Google Scholar
  9. 9.
    Kumar V, Chambon P: The estrogen receptor binds tightly to its responsive elements as a ligand-induced homodimer. Cell 55:145–156, 1988.Google Scholar
  10. 10.
    Tzukerman M, Zhang X-K, Hermann T, Wills KN, Graupner G, Pfahl M: The human estrogen receptor has transcriptional activator and repressor functions in the absence of ligand. The New Biologist 2:613–620, 1990.Google Scholar
  11. 11.
    Pham TA, Elliston JF, Nawaz Z, McDonnell DD, Tsai M-J, O'Malley BW: Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 88:3125–3129, 1991.Google Scholar
  12. 12.
    Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811–2818, 1990.Google Scholar
  13. 13.
    Murphy CS, Langan-Fahey SM, McCague R, Jordan VC: Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cellsin vitro. Mol Pharmacol 38:737–743, 1990.Google Scholar
  14. 14.
    Murphy CS, Parker CJ, McCague R, Jordan VC: Structure-activity relationships of nonisomerizable derivatives of tamoxifen: Importance of hydroxyl group and side chain positioning for biological activity. Mol Pharmacol 39:421–428, 1991.Google Scholar
  15. 15.
    Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of the prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4741–4745, 1983.Google Scholar
  16. 16.
    Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245–276, 1984.Google Scholar
  17. 17.
    Jordan VC, Koch R: Regulation of prolactin synthesisin vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology 124:1717–1726, 1989.Google Scholar
  18. 18.
    Jordan VC, Koch R, Langan S, McCague R: Ligand interaction at the estrogen receptor to program antiestrogen action: A study with non-steroidal compoundsin vitro. Endocrinology 122:1449–1454, 1988.Google Scholar
  19. 19.
    Green S, Welter P, Kumar V, Krust A, Bornert J-M, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence expression and homology to v-erbA. Nature (Lond) 320:134–139, 1986.Google Scholar
  20. 20.
    Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150–1154, 1986.Google Scholar
  21. 21.
    Tora L, Mullick A, Metzger D, Ponglikimongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8:1981–1986, 1989.Google Scholar
  22. 22.
    Reese JC, Katzenellenbogen BS: Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. J Biol Chem 266:10880–10887, 1991.Google Scholar
  23. 23.
    Jiang S-Y, Jordan VC: Growth regulation of estrogen receptor negative breast cancer cells transfected with cDNA's for estrogen receptor. J Natl Cancer Inst 84:580–591, 1992.Google Scholar
  24. 24.
    Jiang S-Y, Langan-Fahey SM, Stella A, McCague R, Jordan VC: Point mutation of estrogen receptor (ER) at the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNA's for ER. Mol Endocrinol 6:2167–2174, 1992.Google Scholar
  25. 25.
    LaBarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344–352, 1980.Google Scholar
  26. 26.
    Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci 32:1031–1036, 1983.Google Scholar
  27. 27.
    Carson-Jurica MA, Schrader WT, O'Malley BW: Steroid receptor family: Structure and functions. Endocrine Rev 11:201–220, 1990.Google Scholar
  28. 28.
    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics 25:127–205, 1984.Google Scholar
  29. 29.
    Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534–540, 1990.Google Scholar
  30. 30.
    Wilding G, Chen M, Gelmann EP: Aberrant responsein vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103–115, 1989.Google Scholar
  31. 31.
    Schuurmans ALG, Bolt J, Veldscholte J, Mulder E: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Molec Biol 37:849–853, 1990.Google Scholar
  32. 32.
    Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703–713, 1992.Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Shun-Yuan Jiang
    • 1
  • Christopher J. Parker
    • 1
  • V. Craig Jordan
    • 1
  1. 1.Department of Human OncologyUniversity of Wisconsin Comprehensive Cancer CenterMadisonUSA

Personalised recommendations